Z-VAD-FMK

Catalog No.S7023

Z-VAD-FMK Chemical Structure

Molecular Weight(MW): 467.49

Z-VAD-FMK is a cell-permeable, irreversible pan-caspase inhibitor, blocks all features of apoptosis in THP.1 and Jurkat T-cells.

Size Price Stock Quantity  
USD 117 In stock
USD 470 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

8 Customer Reviews

  • (A) LAN5 cells were untreated (top panels) or treated with 50 µM of the caspase inhibitor Z-VAD-FMK (bottom panels). Cells were co-treated with nothing (No Rx), 1 µM GSK-J4, or 1 µM venetoclax for 48 hours and assayed for apoptosis by flow cytometry.

    Science, 2018, 10(441), doi: 10.1126/scitranslmed.aao4680. Z-VAD-FMK purchased from Selleck.

    HepG2 cells were pretreated with Z-VAD-FMK for 2 hours followed by treatment with IsoA for 16 hours, and the apoptotic cells were evaluated and quantified by Annexin V/7-AAD staining and flow cytometry. The mean±SD of three experiments is shown.***, P < 0.001

    Cancer Res, 2017, 77(4):926-936. Z-VAD-FMK purchased from Selleck.

  • MM.1S cells were incubated with or without pan-caspase inhibitor Z-VAD-FMK for 1 h and then treated with DCZ3301 (4 μM) for 48 h followed by assessment of cell apoptosis using Annexin V/PI staining. Columns (right panel) represent the average percent of Annexin V positive cells from three independent experiments, which are shown as the mean±SD.

    Theranostics, 2017, 7(15):3690-3699. Z-VAD-FMK purchased from Selleck.

    After treatment with 1.5 g/l matrine in the presence or absence of 10 nM Baf A1 or 20 nM rapamycin or 10 lM z-VAD-FMK (zVAD) for 24 hrs, the cell viability was measured by CCK-8 assay. Results were expressed as mean±S.E.M. representing at least three independent experiments. *P < 0.05, versus matrine alone group.

    J Cell Mol Med, 2017, 21(6):1171-1181. Z-VAD-FMK purchased from Selleck.

  • Z-VAD-FMK (ZVF) reversed K562 cell apoptosis induced by imatinib (IM) and/or hUC-MSCs-Exo. **P < 0.01 versus K562 + IM group, ##P < 0.01 versus K562 + IM + hUC-MSC-Exo group.

    Cytotherapy, 2018, 20(2):181-188. Z-VAD-FMK purchased from Selleck.

    (A and B) Western blot analysis examining the effect of zVAD-fmk on the icaritin-induced apoptosis. The caspase inhibitor zVAD-fmk could significantly decrease the icaritin-induced cleaved caspase-3 expression. β-Actin protein levels indicate that an equal amount of protein was loaded into each lane.n=3. Mean±SD. bP<0.05, compared to the control group. eP<0.05, compared to the icaritin-treated group.

    Acta Pharmacol Sin 2014 35(4):531-9. Z-VAD-FMK purchased from Selleck.

  • Active caspase-3 expression analysis. SW1116 cells were treated with ZBH-1205, CPT-11 and SN38 at 25 μmol/L for 48 h, in the presence or absence of Z-VAD-FMK (50 μmol/L, 1 h ahead of time). *P= 0.0345. Z-VAD-FMK(-) vs. Z-VAD-FMK(+). E: Cell cycle analysis. F: Apoptosis analysis. #P=0.0259. Z-VAD-FMK(-) vs. Z-VAD-FMK(+). ALL experiments were repeated three times.

    Arch Biochem Biophys, 2016, 604:74-85.. Z-VAD-FMK purchased from Selleck.

    Effect on the RAS of CFZ, z-VAD-fmk, or CFZ + z-VAD-fmk treatments administered 5 or 12 days after C26 inoculation and control groups. Western blot analysis of ATF2 and pATF2. CP, ZP and UP were treated for 5 days; CT, ZT, UT and CC were treated for 12 days. CFZ (CP), z-VAD-fmk (ZP), CFZ + z-VAD-fmk (UP), PBS only (CC), healthy control (HC).

    Med Oncol, 2015, 32(4): 538 . Z-VAD-FMK purchased from Selleck.

Purity & Quality Control

Choose Selective Caspase Inhibitors

Biological Activity

Description Z-VAD-FMK is a cell-permeable, irreversible pan-caspase inhibitor, blocks all features of apoptosis in THP.1 and Jurkat T-cells.
Features A key compound for apoptosis studies.
Targets
Pan-caspase [1]
(THP.1, Jurkat T-cells)
In vitro

Z-VAD-FMK (10 mM) inhibits apoptosis in THP.1 cells. Z-VAD-FMK (10 μM) inhibits activation of PARP protease activity in control THP.1 cell lysates. Z-VAD-FMK (10 mM) inhibits the processing of CPP32 in intact THP.1 and Jurkat cells. [1] Z-VAD-FMK (50 μM) cotreatment abolishes the apoptotic morphology of camptothecin-treated HL60 cells. Z-VAD-FMK (50 μM) blocks camptothecin-induced DNA fragmentation in HL60 cells. [2] Z-VAD-FMK (50 μM) inhibits cell death following dSMN dsRNA-induced apoptosis in S2 cells. Z-VAD-FMK (50 μM) increases the percentage of transfected cells surviving from 26% to 63% in S2 cells. [3] Z-VAD-FMK (> 100 μM) enhances TNFα-induced neutrophil apoptosis, lower concentrations (1-30 μM) completely blocks TNFα-stimulated apoptosis in human neutrophils. [4] Z-VAD-FMK (10 mM) inhibits apoptosis in anterior stromal keratocytes. Z-VAD-FMK (10 mM) inhibits apoptosis in anterior stromal keratocytes detected with the TUNEL assay. [5]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
GC1a NX72Z4poSXCxcITvd4l{KEG|c3H5 M1e2d|Ux|ryP NW\OeJB{OjSq NUD3[WdDcW6maXPheIV{KGFicILveIVkfGm4ZTDl[oZm[3RiYXfhbY5{fCCndH;wc5Nq\GV? NVXHTpp1OjZzNkmwO|U>
HGL5 Mof4RZBweHSxc3nzJGF{e2G7 MmDVOVDPxE1? NUXqSHVPOjSq MlW0bY5lcWOjdHXzJIEheHKxdHXjeIl3\SCnZn\lZ5Qh[WejaX7zeEBmfG:yb4Pp[IU> NXTaSmU4OjZzNkmwO|U>
HepG2 MkPERZBweHSxc3nzJGF{e2G7 MonINlDPxE1? MVKxbC=> M1ztO4F1fGWwdXH0[YQhfGinIHHwc5B1d3SrYzDpcoR2[3Srb36gc4YhUUmLLUGwxsA> Mnm2NlYyPjR5OUW=
BEL-7402 M17zUWFxd3C2b4Ppd{BCe3OjeR?= NVvONVhPOjEQvF2= NIjod|QycA>? NInFVlBifHSnboXheIVlKHSqZTDhdI9xfG:2aXOgbY5lfWO2aX;uJI9nKEmLST2xNOKh NXe2NoF3OjZzNkS3PVU>
CEF NVrJTZV7U2mwYYPlJGF{e2G7 MV2wMFM{NDZ5LEGwNO69VQ>? MXWxOY1qdg>? NGmyZ4xld3ewLYLl[5Vt[XSnczDQVkBmdnq7bXWgZYN1cX[rdImgeI8hPDExvJWgZZQhOTByzszN NWG3R5dLOjZzMEKzN|k>
SP2/0 NHHn[llCeG:ydH;zbZMhSXO|YYm= MkDpNVAx|ryP NYfqTGx3OWh? M1H1cGROW09? NV:3dHFH[myxY3vzJJRp\SCjcH;weI9{cXNib3[gV3AzNzBiY3XscJM> NGLJRmYzPjB5NEezNi=>
HUVEC-2c MV7BdI9xfG:|aYOgRZN{[Xl? NHnu[|Q2OM7:TR?= NULFVmVpPmh? Mnvo[IVkemWjc3XkJJRp\SCxeD3MSGwucW6mdXPl[EBifXSxcHjh[5k> M4[2OFI3ODJzN{K5
U1 MYPBdI9xfG:|aYOgRZN{[Xl? MV6wMVExOM7:TR?= NULQ[5NlOmh? MlHYdoVlfWOnczDkdpVoNWmwZIXj[YQh[XCxcITvd4l{KGGwZDDzeYJ{\XG3ZX70JGhKXi1zIILldIxq[2G2aX;uJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy MkXuNlU6QDB7NEK=
ACH-2 M332dGFxd3C2b4Ppd{BCe3OjeR?= NUTw[lQxOC1{MEFOwG0> M1P2OFJp NGXxNpdz\WS3Y3XzJIRzfWdvaX7keYNm\CCjcH;weI9{cXNiYX7kJJN2[nOncYXlcpQhUEmYLUGgdoVxdGmlYYTpc44hcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> Mln6NlU6QDB7NEK=
U1 NXjDbllsU2mwYYPlJGF{e2G7 M{O3[lExOM7:TR?= MUWybC=> NF7SO5RqdmirYnn0d{Bk[XOyYYPlMVM> Ml\NNlU6QDB7NEK=
A549/V16 NYHjS4JmSXCxcITvd4l{KEG|c3H5 MVe1NO69VQ>? MkDuNYg> NYDIPHhiemWycnXzd4V{KFSJL2TNMYlv\HWlZXSgZZBweHSxc3nz NVvQZXd4OjV7NE[wN|M>
SGN NFLhR4ZCeG:ydH;zbZMhSXO|YYm= M17WRVIxdU1? M4T5PVQ5cA>? NYH0ZXdKcGG|IH7vJIlv\my3ZX7j[UBwdiCDSV[sJINidHCjaX6g[ZhxemW|c3nvckBweiClZXzsJIFxd3C2b4Ppdy=> NIfk[5QzPTh5NE[zNy=>
HCT116  NEfnb|JCeG:ydH;zbZMhSXO|YYm= MY[1NO69VQ>? NEP1SZczcA>? NXvaem9LcW6qaXLpeJMhfGinIHPlcIwh\GWjdHigbY5lfWOnZDDifUBFTF[S MX[yOVg3QDhzOB?=
DTK-SME M2X3V2Fxd3C2b4Ppd{BCe3OjeR?= MYO1NO69VQ>? M2i0e|Jp NYi0bpBzTE2VTx?= M4\qVZBienSrYXzsfUBqdmirYnn0d{B1cGViYYDvdJRwe2m|IHnu[JVk\WRiYomgZpVxcX[jY3HpcoU> MViyOVg1Ozh7Nx?=
HL-60 MVLBdI9xfG:|aYOgRZN{[Xl? M{fsRlUx|ryP NGPNVXQ1QGh? M4DweZJm\HWlZYOgZ4VtdCCmZXH0bEBk[XW|ZXSgZpkhW0uLLVnJJJRz\WG2bXXueOKh M3[yOFI2QDJ2MESz
U937 MlT2RZBweHSxc3nzJGF{e2G7 MoDBOVDPxE1? MkP0OFhp M2\tbpJm\HWlZYOgZ4VtdCCmZXH0bEBk[XW|ZXSgZpkhW0uLLVnJJJRz\WG2bXXueOKh M1f5OlI2QDJ2MESz
A549 MV3BdI9xfG:|aYOgRZN{[Xl? NIrmOWMzOCEQvF2= NWDjbnQxOjSq MmDIdoVlfWOnczDj[YxtKGSnYYToJINifXOnZDDifUBJTkOSIITy[YF1dWWwdB?= NWTTO3JZOjV5OUSxOFk>
HeLa MUPBdI9xfG:|aYOgRZN{[Xl? MWSxNO69VQ>? M1;Pb|Q5cA>? NWfmT2J5\GWlbHnu[ZMhfGinIILheIUhd2ZiYYDvdJRwe2m|IHTyZY1ifGmlYXzsfS=> MmXSNlU4PzJ3NEW=
SGC-7901 NHG2RppCeG:ydH;zbZMhSXO|YYm= NXn3ZZp1OjEEoN88US=> NE[3XWMycA>? MVnpcohq[mm2czD0bIUh[2WubDDk[YF1cCCrbnT1Z4VlKGK7IH;4ZYxqeGyjdHnu M2rLRVI2PzZ5MEe2
MCF-7 Ml3sRZBweHSxc3nzJGF{e2G7 MUSxNO69VQ>? NVPWS3U3Omh? MXPpcohq[mm2czD0bIUh[2WubDDk[YF1cCCrbnT1Z4VlKGK7IEPC NFq3WJYzPTd{MkGxOC=>
A549 NIPq[XhCeG:ydH;zbZMhSXO|YYm= M2DtUVExKM7:TR?= NHzRfHAzPGh? MUTEUXNQ M1XM[pBzd22xdHXzJGhDSy22cnXheIVlKEF3NEmgZ4VtdCC|dYL2bZZidCBoIHH0eIVvfWG2ZYOgeIhmKGOuZXH2[YQhWEGUUDDlfJBz\XO|aX;u NHTsZYEzPTZ6M{W2PC=>
U87 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGi1dJA2OM7:TR?= NIrTZ20ycA>? NUfwV|hsemWlb4\ldpMh[2WubDDndo94fGhiZoLvcUBVVVpidILlZZRu\W62 NGrvWXEzPTZ6MU[2PC=>
Neocortical Neuron NG\oZYtP\XW{b4TvfIlkcXS7IFHzd4F6 NEHSdHYyODEQvF2= M3rsWVFp Ml\5ZY51[Wexbnn6[ZMhUG:rYX3p[IUhSS2LbnT1Z4VlKE6ndYLveI95cWOrdIm= NF;sVpEzPTZ5NUCwNS=>
Primary human placental cytotrophoblasts Moq5RZBweHSxc3nzJGF{e2G7 NV3ocoZxOzEQvF2= MWCyOIg> MV\EUXNQ MkW0doV3\XK|ZYOgeIhmKGmwaHnibZRqd25ib3[gNVHPui2KU1SyJIJ6KHS{aXPsc5NidsLi NV3tSo9rOjV4NEK1PVI>
MM MofQRZBweHSxc3nzJGF{e2G7 NWfrPWlzPTEQvF2= M1TNeFIxdWmw M{fEc5BienSueTDpcohq[mm2czDTTGsucW6mdXPl[EAh[2WubDDk[YF1cA>? MUeyOVU{ODB7OB?=
DLD1 MVHBdI9xfG:|aYOgRZN{[Xl? NFrJWYQzOMLizszN MUOxbC=> NUfnfIxyeGG{dHz5JJJmfmW{c3XzJINmdGxiYYDvdJRwe2m|IHPheZNm\CCkeTDXV3Ay NF3tOJMzPTV{NEK0Oi=>
MDA-MB-231 NYqzWnJWS3m2b4TvfIlkcXS7IFHzd4F6 NV[xfIU4OTEQvF2= NHf6S3kycA>? M1fnW4F2\22nboTzJINmdGxiZHXheIgh[W[2ZYKgR2hWSSC2cnXheI1mdnR? NVjibXFuOjV3MkG1NFE>
MKN28 M3\kdmFxd3C2b4Ppd{BCe3OjeR?= MliyNVDPxE1? M2X2NlMxdWmw NWjkRmdITE2VTx?= MkTkbY5pcWKrdIOgWG5HNc7zIIDseZMhS0i[LXnu[JVk\WRiYYDvdJRwe2m| MWOyOVUyOzl4MB?=
HL-60 MVLDfZRwfG:6aXPpeJkhSXO|YYm= NVTx[oYyOTByzszN MkLFNYg> M135b2ROW09? MVtCpIlueHKxdnXzJJZq[WKrbHn0fUBw\iCWQ17Bd{11emWjdHXkJINmdGy| MnTJNlU2ODJ7M{K=
AGS MYLBdI9xfG:|aYOgRZN{[Xl? MojWNVDPxE1? M1qwPFFp MVfwdoV3\W62czDjeZJkfW2rbj3pcoR2[2WmIHPs[YF3[WenIH;mJINie3Cjc3WtN{whNThuIHHu[EAuQSCycn;0[Ylvew>? M1:1ZVI2PDl{MkG0
A549  NEfqe|BCeG:ydH;zbZMhSXO|YYm= M1XQ[VEx|ryP NFHkRo8zPGh? NIrVUXRjdG:la4OgSG1CWy2rbnT1Z4VlKGOuZXH2ZYdmKG:oIHPhd5Bie2VvMzDhcoQhWEGUUDDhcoQh[XCxcITveIlkKGOnbHyg[IVifGh? MmDPNlU1OzR7OEm=
INS-1 M1\p[WFxd3C2b4Ppd{BCe3OjeR?= NEXYWGM2OM7:TR?= M1[2elZp NH3H[4pFVVOR Mkjo[IVkemWjc3XzJJRp\SCycn;wc5J1cW:wIH;mJIViemy7IHHwc5B1d3SrYzDj[Yxte8Li M1X2SlI2PDNyOEm3
Primary hepatocytes  M{\nemFxd3C2b4Ppd{BCe3OjeR?= MV:1NO69VQ>? MYexPIg> NITDOohqdmirYnn0d{BieG:ydH;zbZMhd2ZiaHXwZZRw[3m2ZYOgbY5lfWOnZDDifUBC[3RiRDDhcoQhXE6ILd8x NGHWNFkzPTRyN{WzPC=>
L929-A  NV2wRocyS3m2b4TvfIlkcXS7IFHzd4F6 NVjw[3RKOjEEoN88US=> MXGyOIg> NInQOplqdmirYnn0d{BVVkcQsT3pcoR2[2WmIHPlcIwh\GWjdHi= MViyOVM6QDV2MB?=
L929-N MVLDfZRwfG:6aXPpeJkhSXO|YYm= MYiyNOKh|ryP MUOyOIg> MWHlcohidmOnczDk[YF1cCC4aXGgZZV1d2O{aX7lJHRPTs7zIIDyc4R2[3Srb36= MlTLNlU{QTh3NEC=
Cytotoxicity Assay M{f0d2NmdGxiVnnhZoltcXS7IFHzd4F6 NYq5Tm9zOjEQvF2= MlnjOFhp NHXmR5VxemW4ZX70JG1JVURvaX7keYNm\CClZXzsJIRm[XSq MkXDNlU{QTJzMU[=
COS7 MlXHT4lv[XOnIFHzd4F6 MWSxNO69VQ>? M4L2TVI1cA>? MlPnbY5kemWjc3XzJINie3Cjc3WgN{84KGGldHn2bZRq\XN? M{mwXFI2Ozh2MEK1
COS7 MmHmRZBweHSxc3nzJGF{e2G7 NF[yNVEyOM7:TR?= NYPMNlU4PDiq MWTwZZJ1cWGubImgdJJmfmWwdHXkJGZEOTBzLXnu[JVk\WRiY3XscEBl\WG2aB?= NFHxcoQzPTN6NECyOS=>
A375 MkjPRZBweHSxc3nzJGF{e2G7 NGjU[FQ{OM7:TR?= NUS5RVV[Omh? Mo\QdJJmfmWwdIOgeIhmKGS{dXetbY5lfWOnZDDQRXJRKGOuZXH2ZYdm MX2yOVM4PjFzNR?=
A549 MmPuRZBweHSxc3nzJGF{e2G7 NYi3b4dWPTEQvF2= MmDDNlRp NGTOXXVz\X[ncoPld{BzcWKxc3;t[UBjcW:pZX7ld4l{KGGwZDDhdI9xfG:|aYOgZ4F2e2WmIHL5JEBEcGmsb37n[IFv NHvHPWwzPTN2OUe4NS=>
A549 MnHIRZBweHSxc3nzJGF{e2G7 MXGyMlUuOjYQvF2= Mm\kNYg> MX3k[YNz\WG|ZYOgeIhmKHCxcIXsZZRqd25ib3[gZZBweHSxdHnjJINmdGy|IHTldIVv\CCxbjDjc45k\W62cnH0bY9vew>? MoG3NlU{PDJ2Mke=
 NBL-W-S  MW\BdI9xfG:|aYOgRZN{[Xl? NUD3RmZDPTEQvF2= MVexbC=> MX;meYxtgSC{ZYPjeYV{KGOnbHygeoli[mmuaYT5JIFnfGW{IFfBUnQuPjFidILlZZRu\W62 MoDDNlU{OjN{MkK=
Caki-1  MUXBdI9xfG:|aYOgRZN{[Xl? NHzlc3U1OM7:TR?= MmizOFhp MoG1doVlfWOnczD0bIUhdnWvYnXyJI9nKEGwbnX4bY4hXi2yb4PpeIl3\SClZXzsdy=> NHjuOZEzPTJ5OUG5NS=>
769-P MXnBdI9xfG:|aYOgRZN{[Xl? MWq0NO69VQ>? NIC0VpE1QGh? NVvReW53emWmdXPld{B1cGViboXtZoVzKG:oIFHucoV5cW5iVj3wc5NqfGm4ZTDj[Yxtew>? NVnYWYxHOjV{N{mxPVE>
H9c2 MlrNRZBweHSxc3nzJGF{e2G7 MWS1NO69VQ>? NHPqW20ycA>? NF;TbHNqdmirYnn0d{BFV1hvaX7keYNm\CClYYPwZZNmKDNiYXP0bZZifGmxbjDieZQhdm:2IITo[UBtd3O|IH;mJINmdGy| MWGyOVI5OzhzOR?=
K562 M{HUXmFxd3C2b4Ppd{BCe3OjeR?= MnvGOVDPxE1? M2GzdlRp M3PJWolvcGmkaYTzJGpi[y2DLXnu[JVk\WRiY3XscEBieG:ydH;zbZM> M2PTfVI2OjRzNkG5
L929 NXzhPYt7SXCxcITvd4l{KEG|c3H5 NWXvTZJNOTEQvF2= Mkm5Oog> Mm\qbY5lfWOnczDu[YNzd3C2b4Ppd{B4cXSqIGTOSi=> NXTD[YY6OjVzOUW2OlA>
A549 MV3BdI9xfG:|aYOgRZN{[Xl? NInrPFQyOM7:TR?= NFLVNHc{cA>? MXfy[YR2[2W|IHPlcIwh[XCxcITvd4l{KGOjdYPl[EBjgSCSUWG= NGG0U|MzPTF4MU[5PS=>
MCF-7 MVzBdI9xfG:|aYOgRZN{[Xl? NWTNRnRrOjEQvF2= NFy2U4QzcA>? NIPibJll\WO{ZXHz[ZMhU0SULYPpVm5CNWmwZIXj[YQh[XCxcITvd4l{ MVmyOVE5OjJ2MB?=
OS MXHBdI9xfG:|aYOgRZN{[Xl? NH\pN|MzOC92MN88US=> NWPGZ|NLPzKq MUPpcohq[mm2czDPV{Bk\WyuII\pZYJqdGm2eTDy[YR2[3Srb36gZpkhSzZiY3XyZY1q\GV? Ml;VNlUyPTJ|OUm=
HUVECs M1\tOmFxd3C2b4Ppd{BCe3OjeR?= NVO4OZVCOTEQvF2= MmPSNog> NU\kb|loyqCrbnjpZol1eyCjcH;weI9{cXNiYX7kJIZi[2muaYTheIV{KGG3dH;wbIFogSCrbjDESW5XOi2rbn\lZ5Rm\CCKVW\FR5M> NVzqeZpZOjVzM{i3NFM>
EA.hy926 M{iwSmFxd3C2b4Ppd{BCe3OjeR?= NXz6XoxoOTEQvF2= NX[wWVJyOmh? MlXzxsBqdmirYnn0d{BieG:ydH;zbZMh[W6mIH\hZ4ltcXSjdHXzJIF2fG:yaHHnfUBqdiCGRV7WNk1qdm[nY4Tl[EBGSS6qeUmyOi=> MViyOVE{QDdyMx?=
Ebs M{i3SmFxd3C2b4Ppd{BCe3OjeR?= MV:xNE0yODEQvF2= MWCyOIg> NInoV|HDqE2PVGOg[4Vv\XKjdHnvckBz[XSnIHTlZ5Jm[XOnZDDhd{B1cGViY3;uZ4VvfHKjdHnvckBw\iC8LW\BSE5ndWtiaX7jdoVie2Wm NWrVNFUyOjVzM{S4NVc>
Jurkat NI[3V5pCeG:ydH;zbZMhSXO|YYm= M3XmclIx|ryP MYGyOIg> MVnEUXNQ Mmr3dIFzfGmjbHz5JIlvcGmkaYSgZ4VtdCCmZXH0bEBw\iCMdYLrZZQh[2WubIOgbY5lfWOnZDDifUAyODB3OD3GOEBkd22kaX7l[EB4cXSqIG\QReKh M13HOlI2OTJyN{Kz
K562 NXm0W4ozSXCxcITvd4l{KEG|c3H5 NW[wNpd7OC5zLUJOwG0> M4TGT|Fp MYnpcohq[mm2czDjcIVifmGpZTDv[kBJW1B7MDDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= MYWyOVEyQTF6OB?=
IMR-32 MX7BdI9xfG:|aYOgRZN{[Xl? NGmwXYk1OMLizszNxsA> MnfMNog> MlP1[IVkemWjc3WgbY4h[XCxcITveIlkKGOnbHzzJINwdXCjcnXkJJRwKFRvMjD0c5hqdg>? NXXCbWRTOjVyOES3OVU>
RPMI 8226 M1PvdmFxd3C2b4Ppd{BCe3OjeR?= NEHBNGwyODEQvF2= MofpNYg> MmO3ZYxud3O2IHPvcZBt\XSnbImgZoxw[2u|IHPlcIwh\GWjdHigZ4F2e2WmIHL5JI5m[3Kxc4TheIlvNTF? MlHENlUxOzd6NUG=
U266  Ml\xRZBweHSxc3nzJGF{e2G7 MnHONVAx|ryP MXGxbC=> Ml;tdIFzfGmjbHz5JIJtd2OtczDj[YxtKGSnYYToJINifXOnZDDifUBv\WO{b4P0ZZRqdi1z MV6yOVA{Pzh3MR?=
H929  NUjPToFVSXCxcITvd4l{KEG|c3H5 MoCwNVAx|ryP MYqxbC=> NWqwfWN[eGG{dHnhcIx6KGKub3Prd{Bk\WyuIHTlZZRpKGOjdYPl[EBjgSCwZXPyc5N1[XSrbj2x NVPaWJh[OjVyM{e4OVE>
MM.1S  Ml\2RZBweHSxc3nzJGF{e2G7 MXexNFDPxE1? MlLCNYg> NYHkc2FI\W[oaXPp[Y51dHlicILleoVvfHNic3;yZYZmdmmkLXnu[JVk\WRiY3XscEBl\WG2aDDjc41jcW6nIIfpeIghdmWlcn;zeIF1cW5vMR?= NIHHfWUzPTB|N{i1NS=>
C6 MknMRZBweHSxc3nzJGF{e2G7 MUO1NO69VQ>? NIjhZ2g1QGh? NHn5N21xemW4ZX70d{B1cGVibH;zd{Bw\iClZXzsJJZq[WKrbHn0fUBk[XW|ZXSgZpkheHKnZ37lco9td26n NH\GN24zPTBzM{S3PS=>
AGS MWTBdI9xfG:|aYOgRZN{[Xl? NFLLSG82OM7:TR?= NWP6PYY6OjSq MWHhZo9tcXOqczFOtk1t[XCjY3jvcoUucW6mdXPl[EBk\WyuIHTlZZRpKGGwZDDpcohq[mm2ZXSg[5Jwf3Sq NF6yZWMzPTByOU[5PC=>
HeLa  M3HnU2Fxd3C2b4Ppd{BCe3OjeR?= NU\VV29[PDEQvF2= M1uyeFI1cA>? NIXhWpNqdmirYnn0d{B1cGViaX7jdoVie2WmIHHwc5B1d3OrczDpcoR2[2WmIHL5JJNqWk6IMUKx NF\4O|kzPDl{OE[4OS=>
THP-1  NIPoNndCeG:ydH;zbZMhSXO|YYm= MUWxNO69VQ>? MlnENYg> NYnrZpRRemWmdXPld{BieG:ydH;zbZMhcW6mdXPl[EBjgSCDTFGtV2RVyqB? MWKyOFkzOzZ3Mx?=
P815  NH\MO4hCeG:ydH;zbZMhSXO|YYm= M1rie|ExOCEEtV2= MofzNVJp NIXqZZNFVVOR NUPkb3BWcW6qaXLpeJMhfmm{dYOtbY5lfWOnZDDhdI9xfG:|aYO= MoniNlQ6OjN{N{O=
HCT116 MofURZBweHSxc3nzJGF{e2G7 NU\SOnVsOjEQvF2= NHHwTnIzPGh? MnXrZYJzd2ejdHXzJI9nKFSTLXnu[JVk\WRiYYDvdJRwe2l? MorFNlQ5QTB2NEm=
SW1116  NEnIZY9CeG:ydH;zbZMhSXO|YYm= NVvmWopuOTBiwsXN MlXSNYg> NFTYbGRFVVOR M4PsTZJme3S{YXnud{Bk\WyuIHHwc5B1d3OrczDpcoR2[2WmIHL5JIdm\mm2aX7pZkBxdHW|IHTlZ4l1[WKrbnW= NES5VHgzPDh5NEK4Oi=>
LOVO NWX3NXNqSXCxcITvd4l{KEG|c3H5 MYexNEDDvU1? MWmxbC=> M{DxZmROW09? MU\y[ZN1emGrboOgZ4VtdCCjcH;weI9{cXNiaX7keYNm\CCkeTDn[YZqfGmwaXKgdIx2eyCmZXPpeIFjcW6n NHn5fo8zPDh5NEK4Oi=>
SNU449  Mk\mRZBweHSxc3nzJGF{e2G7 NEfkflYzOM7:TR?= MXO0PIg> NIGwPIFFVVOR Mn71[IVkemWjc3XzJI1qWi12NUGtbY5lfWOnZDDhdI9xfG:2aXO= M1ewSlI1QDRzNkO4
Caco-2 NWLWdHkySXCxcITvd4l{KEG|c3H5 MoCwOFDjiIoQvF2= NVr6dYM2PGh? NX\oXZBkeHKndnXueJMhW1RvNz3pcoR2[2WmIGrPMVEh[2ijbnfld{BidmRiVFXSJIRzd3B? MXKyOFgzOjF6Mx?=
macrophage M17NN2NmdGxiVnnhZoltcXS7IFHzd4F6 NUL4NllJOC1{MEFOwG0> M3fEV|I1cA>? MULpcoR2[2W|IGTOSk0h[W6mIGLpdFMu\GWyZX7k[Y51KG6nY4LvdJRwe2m|IHnuJI1i[3KxcHjh[4U> NGjzfmgzPDd7OUW2OS=>
AGS  NVHjeIdqSXCxcITvd4l{KEG|c3H5 MmrENlDPxE1? NVXkcGJOOTKq NGDqSm1FVVOR NWj3UFJOemWmdXPld{B1cGViaX7keYN1cW:wIH;mJIFxd3C2b4Ppd{BqdiC{ZYPwc45{\SC2bzD0bIUhTXSRQXOg[pJi[3Srb36gbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= MXOyOFc5QTdyMx?=
LCC9  MVzD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NYHr[nBVOTByzszN NFLoRWI2\A>? NFX4coZjdG:la4OgZ4VtdCCmZXH0bEBqdmS3Y3XkJIJ6KGOxbXLpcoF1cW:wIFyxO{BidmRiY3jsc5JweXWrbnW= MWqyOFc5PTJ3Nh?=
U937  NX3OOpdZdmWlcn;weI9{cXNiQYPzZZk> NYTxe4tmOTEEoN88US=> M3zwe|MxyqCvaX6= MYHpcoR2[2W|IH7lZ5JweHSxc3nzJINwdWKrbnWge4l1cCCWTl[= MWKyOFc4Ozd3Nh?=
T cell Mk\vR4VtdCCycn;sbYZmemG2aX;uJIF{e2G7 MlHjNE0yODEQvF2= MUO3Nog> NX;OTJYzUUN3ME23NEDPxE1uIHnubIljcXS|IHHueIkuS0R|LXnu[JVk\WRiVDDj[YxtKHC{b3zp[oVz[XSrb36gbY4hWEKPQ4O= NF\uU3UzPDd4OEewOy=>
HeLa  MV;BdI9xfG:|aYOgRZN{[Xl? NHrHWYo2OM7:TR?= M{\Q[VczcA>? MV;EUXNQ MkPpdJJmfmWwdIOgZZBweHSxc3nzJIlv\HWlZXSgZpkh[2:vcH;1coR{yqBz4pETOS=> MUKyOFc2PDd6Nh?=
HeLa  MVvBdI9xfG:|aYOgRZN{[Xl? NH\sN|EyODEQvF2= M{HiR|I1cA>? MUPzeZBxemW|c3XzJJJifGVib3[gZ4VtdCCmZXH0bEBqdmS3Y3XkJIJ6KG:4ZYLlfJBz\XO|aX;uJI9nKEd3OWOgc5IhTzdzUjDwNVUx\2y3ZXVCpC=> NX3FRph7OjR5MkK0Olg>
IEC-6  Mk\rRZBweHSxc3nzJGF{e2G7 NHPWOYQyOM7:TR?= NVXwc3J4OjSq MUnwdoV3\W62czDUZ4RCNWmwZIXj[YQh[2G|cHHz[U0{KGOuZXH2ZYdmKGGwZDFOtk1k[XSnbnnuJIRm\3KjZHH0bY9v M4LDWFI1PzFzNUex
HCT116 NUjlVYN7SXCxcITvd4l{KEG|c3H5 Mo[zNlDPxE1? NYfXXG5vOjSq MlHnbY5pcWKrdIOgeIhmKGOnbHygZZBweHSxdHnjJIlv\HWlZXSgZpkhYUyWMkC1 NETuNoIzPDdzM{ixNi=>
L02 MoD2RZBweHSxc3nzJGF{e2G7 MUiyNO69VQ>? Mly1NYg> NYfxSmQxeHKndnXueJMhfGinIHPlcIwh[XCxcITvd4l{KGmwZIXj[YQh[nliTVXIVC=> NECxcGwzPDdyNkS2NS=>
A375 Moi0RZBweHSxc3nzJGF{e2G7 NIHaO4YzOM7:TR?= NUTOXVN[OjSq NXvEbJFFemW4ZYLz[ZMh\GmlaYTybY5wdmViQj3pcoR2[2WmIHHwc5B1d3Orcx?= NFHGR3AzPDZ7OUGxNS=>
HDPC NWrab21jSXCxcITvd4l{KEG|c3H5 M1\qdlUxyrWP M{DoSlI1cA>? Mn\YbY5pcWKrdIOgUm8ucW6mdXPl[EBieG:ydH;zbZM> M3jyPVI1PjN2NUmz
A549 NHvTfGJCeG:ydH;zbZMhSXO|YYm= NH7ZUFI2OML3TR?= M3vFclJp MmjmSG1UVw>? M331N5Bz\X[nboTzJJRp\SCqeYDv[IlxdG:rZDDEUmEh[2:wdHXueEBxcGG|ZTDpcoR2[2WmIHL5JINmeGijbH;jbJJwdWmw NGnYZo8zPDV6OEGzOS=>
 BV-2 NEHx[2VCeG:ydH;zbZMhSXO|YYm= M17oWVIx|ryP NFzlPHIzcA>? MoXhd5VxeHKnc4Pld{BWXi2rbnT1Z4VlKGOqcn;tZZRqdiCneITyeZNqd25iYX7kJIRqdGG2aX;uJI9nKHSqZTDueYNt\WG{IHXueoVtd3Cn M{nvfFI1PTV6MUG4
HT-29  M4XiRWFxd3C2b4Ppd{BCe3OjeR?= MYK1NO69VQ>? MU[0PIg> NHT5WnRjdG:la4OgeIhmKGGyb4D0c5NqeyCrbnT1Z4VlKGK7IHvh[Y1x\mW{b3y= Ml7yNlQ2PDlzN{W=
A549 NXOxfIlmSXCxcITvd4l{KEG|c3H5 M{HkelXPxE1? Mlj3NlRp MWDzeZBxemW|c3XzJFZmyqBqQluxNFA1OClvaX7keYNm\CCjcH;weI9{cXQEoB?= M{\VVVI1PTJ7OEex
MIA-PaCa-2 NYjhUVRmSXCxcITvd4l{KEG|c3H5 NECydFgzPGh? MWPicI9kc3NiY3zlZZZi\2Vib3[gZ4F{eGG|ZT2zJIlv\HWlZXSgZpkh[m:2aDDBMVQ1OzZ3NDDhcoQheGGlbHn0ZZhmdA>? M{jEclI1PTFyOUmy
Caki-1 MY\BdI9xfG:|aYOgRZN{[Xl? NIjIVWgzOM7:TR?= MoHJNYg> MUnpcohq[mm2czDTR3AucW6mdXPl[EBieG:ydH;zbZM> M{Hqe|I1PTB2Nkix
CLL M4XKXWFxd3C2b4Ppd{BCe3OjeR?= NFzmPZozPc7:TR?= NXHlOVlHOWh? NHzlS2lx[XK2aXHscJkh[myxY3vzJG1NVjJ{M{itbY5lfWOnZDDj[YxtKGGyb4D0c5Nqew>? NHXKVFIzPDR4N{[zOC=>
SGC-7901 NULnWFBlSXCxcITvd4l{KEG|c3H5 NFTRWoEyOM7:TR?= NGfCZnIzPGh? NGn5UoRxem:vb4Tld{B1cGViQ1fJTU1qdmirYnn0[YQh[2WubDDndo94fGhiaX6gV2dENTd7MEGgZ4VtdHN? MkLVNlQ1PTR2OEi=
k1735 NEjMdHhCeG:ydH;zbZMhSXO|YYm= MmL6NlDjiIoQvH2= NYLPZ5hvPGh? NWHIPZpxcW6qaXLpeJPDqFOjbH3vcoVtdGFvaX7keYNm\CCjcH;weI9{cXN? M2L0UlI1PDVzMUG2
HaCaT  NFG3SYNCeG:ydH;zbZMhSXO|YYm= NYTTSYh7OTByzszN NYDWZ2lqOWh? M{jkNoJtfW62czDVWmIucW6mdXPl[EBieG:ydH;zbZMhcW5iSHHDZXQh[2WubIO= M2D2[VI1OzV4OUm3
podocytes Mmf5RZBweHSxc3nzJGF{e2G7 M3jmNVIxOM7:TR?= MoXCOog> NX;ETnRHcW6qaXLpeJMh[XCxcITvd4l{KGmwZIXj[YQh[nliMzy0MWRITQ>? MnqxNlQ{Ozd5N{e=
 KB NH22dGZCeG:ydH;zbZMhSXO|YYm= MVO1NO69VQ>? NXO4eHYyOjSq M2\vUIlvcGmkaYTzJGxq[29vQT3pcoR2[2WmIHPhd5Bie2VvMzDhcoQhWEGUUDDhZ5RqfmG2aX;u Ml:2NlQ{Ozd2OUK=
 HepG2  Mnu0RZBweHSxc3nzJGF{e2G7 NV3NUo5XOTEQvF2= NWr1c5puOjSq MUHy[YR2[2W|II\pcYVvfGmwIHPs[YF3[WenIHPheZNm\CCkeTDMVHM> M3\OXFI1OzJ3OEG2
fetal rat lung fibroblasts  M1HtNmtqdmG|ZTDBd5NigQ>? MUe4NO69VcLi NGP5OocycA>? Moq0bY5pcWKrdIOgR4F{eGG|ZT2zJIFkfGm4aYT5xsA> NWLPUFFIOjR|MUSxN|U>
PDL fibroblasts NUC1fIdLU2mwYYPlJGF{e2G7 MVm4NO69VcLi M1rKc|Fp M2nmTYlvcGmkaYTzJGNie3Cjc3WtN{Bi[3Srdnn0feKh M{O4N|I1OzF2MUO1
MB49 MmfJRZBweHSxc3nzJGF{e2G7 MWSyNO69VQ>? NHm2[HcycA>? Ml:3doV3\XK|ZYOgR20ucW6mdXPl[EBk\WyuIHTlZZRp M3XnSVI1Ojh{NEOz
5637 NVi4VFR7SXCxcITvd4l{KEG|c3H5 M33STFIx|ryP MWGxbC=> M2TRWJJmfmW{c3XzJGNONWmwZIXj[YQh[2WubDDk[YF1cA>? NIPKVGMzPDJ6MkSzNy=>
A549  MkLpRZBweHSxc3nzJGF{e2G7 MYOxNFDPxE1? MXq0PIg> NXLQTooye3WycILld5NmeyC2aHWgZZBweHSxc3nzJINifXOnZDDifUBxcXCncnnu[eKh MkfhNlQzPzJ{MEG=
MCC-2 Ml;qRZBweHSxc3nzJGF{e2G7 MUSyNEDPxE1? MWi2bC=> MVXEUXNQ NFnjb2ljdG:la4OgbY5lfWOnZDDifUB{fGG3cn;zdI9zcW6nIHHwc5B1d3OrczDj[YxtKGSnYYTo MUmyOFI3OjZ3OB?=
ADF M{HwN2Fxd3C2b4Ppd{BCe3OjeR?= NIrCcWU1OM7:TR?= NVHvVmFXPmh? MlvIbY5pcWKrdIOgZZBweHSxc3nzJIlv\HWlZXSgZpkh[2inbX;0bIVz[XC7IIDseZMhYm6FbEK= NX[1fXF4OjR{MkiyN|I>
 U373  NH24[|BCeG:ydH;zbZMhSXO|YYm= NIe3UJU1OM7:TR?= M3rFSFZp NIXkPJZqdmirYnn0d{BieG:ydH;zbZMhcW6mdXPl[EBjgSClaHXtc5Rp\XKjcImgdIx2eyCcblPsNi=> NH\TUnUzPDJ{OEKzNi=>
RKO-HIPK2i NED2W|ZCeG:ydH;zbZMhSXO|YYm= NXjKR3ZMPDEQvF2= NF7jXnM3cA>? M2n0OolvcGmkaYTzJIFxd3C2b4Ppd{BqdmS3Y3XkJIJ6KGOqZX3veIhmemGyeTDwcJV{KFqwQ3yy MnKyNlQzOjh{M{K=
HEC-1B MXfBdI9xfG:|aYOgRZN{[Xl? MlrVNlDPxE1? NEXjNmwycA>? MmLtdoVlfWOnczDUVE1qdmS3Y3XkJIFxd3C2b4Ppd:Kh[2G|cHHz[U0{KGGwZDDjZZNx[XOnLUm= NUPuWFBUOjR{MUOzOVg>
4T1 M4XqZ2NmdGxiVnnhZoltcXS7IFHzd4F6 Mkf0Nk42NTFyzszN NG\4T5I1cA>? NIXRfmRFVVOR NV25bWt1emW|Y4Xld{B1cGViY4n0c5RwgGmlaYT5JI9nKDSWMTDj[YxteyCrbnT1Z4VlKGK7IGPQSHQhcW5iYTDjc45k\W62cnH0bY9vKGSncHXu[IVvfCCvYX7u[ZI> MX6yOFIxPjF4MR?=
OS  M2S1c2Fxd3C2b4Ppd{BCe3OjeR?= NF;keokzOM7:TR?= NEC5OJI1cA>? MlnubY5pcWKrdIOgeIhmKGOnbHyg[IVifGhiY3H1d4VlKGK7IGDEWC=> MlewNlQzODR7M{e=
RPE NW\FV5d2SXCxcITvd4l{KEG|c3H5 M3XMR|ExOM7:TR?= NVXLSmZxPDiq NHPSeYpx[XK2aXHscJkhcW6qaXLpeJMhfGinIHPhcJBicW5vMTDhcoQhNTJiYXP0bZZifGmxbjDhd{B4\WyuIHHzJJRp\SClYYPwZZNmKGGldHn2ZZRqd25? NVX3UJFjOjR{MEKwOVI>
UD29a NFXlZ2RCeG:ydH;zbZMhSXO|YYm= NHnMc2s2OM7:TR?= NFXIS4UzPGh? MV\pcohq[mm2czD0bIUh[2WubDDk[YF1cCClYYXz[YQh[nliTmXUNy=> Mor1NlQyQTB3N{S=
SH-SY5Y  M{fSTmFxd3C2b4Ppd{BCe3OjeR?= NVXxVIhtOTEQvF2= NFnscoszPGh? NIq0R3NifHSnboXheIV{KGOjc4Dhd4Uh[WO2aY\heIlwdiCjbnSgZ4VtdCCmZXH0bEBqdmS3Y3XkJIJ6KEiQRT2ySGc> NEXad|kzPDF2NUS2Ny=>
HeLa  M4XW[2Fxd3C2b4Ppd{BCe3OjeR?= M3fidFExNzJyzszN NXPjS5VqOjSq Mmr3bY5pcWKrdIOgeIhmKGGldHn2bZR6KG:oIITo[UBu[Wqxcnn0fUBw\iC2aHWgcYVu[mW{czDv[kB1cGViY3HzdIF{\S2oYX3pcJk> MnfQNlQyOzd{Nk[=
SCCVII  NY\RZXdCSXCxcITvd4l{KEG|c3H5 MlrENlXPxE1? NG\nTWwycA>? M{jtTYlvcGmkaYTzJJRp\SClZXzsJItqdGyrbnegZYZ1\XJiZHHzZZRqdmmk M2jzd|I1OTJ4NE[0
RAW 264.7 NEXMU5VCeG:ydH;zbZMhSXO|YYm= Mn:0NlDPxE1? MnXKNVhp M1iySolv[3KnYYPld{BNSzNvSVmv{tIu[WO2aX6gdoF1cW9iY3;tdIFz\WRidH:gSWNVXi2PT2OgeJJm[XSvZX70JI9vdHl? MWiyOFEyPjdyNx?=
A549  MmHwRZBweHSxc3nzJGF{e2G7 NVf0eoc4Oi53zszN MlPNNlRp MVzk[YNz\WG|ZYOgc5Jq\G:waX6tbY5lfWOnZDDheZRweGijZ4mgZZMhf2WubDDhcoQhVG:|czDv[kDPnM,KbTDhcJNwKG:lY4XydoVlKGS3cnnu[{BifXSxcHjh[4lkKHC{b3Pld5M> NH\RSIwzPDFyMkWyNi=>
UM-SCC-10A  MnLGRZBweHSxc3nzJGF{e2G7 NV7B[WJlPTEEtV2= NX;McohEOmh? M3zUTpJm\HWlZYOgZZBweHSxc3nzJIlv\HWlZXSgZpkhcGmpaD3kc5NmKGm|b3HsZY51d2yjY4TvcoU> MkPrNlQxQTh5NUO=
BGC-823 Ml\sRZBweHSxc3nzJGF{e2G7 MVixNEDPxE1? NYjLRpJnOjSq M3TKe5Jm\HWlZYOgeIV1emGwZILpcoUucW6mdXPl[EBieG:ydH;zbZPDqA>? MkTwNlQxQTh3MUG=
Nalm-6  NEfpem1CeG:ydH;zbZMhSXO|YYm= NV;3UVkxOjEQvF2= MXK0bC=> NYqxRVRkcW6qaXLpeJMh[2G|cHHz[U05KGGwZDDjZZNx[XOnLUOgZYN1cX[jdHnvckBidmRiUFHSVE0yKGOuZXH2ZYdm Mo[2NlQxOzl7Nke=
KHOS  M4m1fWFxd3C2b4Ppd{BCe3OjeR?= NGLDT3M1OM7:TR?= Mo\QNlRp M1;T[oJtd2OtczD0bIUhcW6lcnXhd4VlKGOuZXH2ZYdmKG:oIHPhd5Bie2VvMzDhcoQhWEGUUDDpcoR2[2WmIHL5JGJDVUR|wrC= NGXWTJAzPDB{NUO2NS=>
G292 NXrQZoxrSXCxcITvd4l{KEG|c3H5 M{K1XlQx|ryP MojGNlRp NYf1ZXpC[myxY3vzJJRp\SCrbnPy[YF{\WRiY3zlZZZi\2Vib3[gZ4F{eGG|ZT2zJIFv\CCSQWLQJIlv\HWlZXSgZpkhSkKPRERCpC=> M2fHdlI1ODJ3M{[x
MG-63 Mmm3RZBweHSxc3nzJGF{e2G7 NFXG[VQ1OM7:TR?= M37ydVI1cA>? MnznZoxw[2u|IITo[UBqdmO{ZXHz[YQh[2ynYY\h[4Uhd2ZiY3HzdIF{\S1|IHHu[EBRSVKSIHnu[JVk\WRiYomgRmJOTDQEoB?= NYf5cIhtOjRyMkWzOlE>
EBV-transformed B cells NU[xNlY{SXCxcITvd4l{KEG|c3H5 NH;BdHYzOM7:TR?= NWHyPZVHOmh? MmPOSG1UVw>? MkD2Zoxw[2u|IHHueIkuS0R6MDDhcoQh[W62aT3DSFg3KGGwdHnic4R6NWmwZIXj[YQh[XCxcITvd4l{ MmTRNlQxODh4Mki=
IM-9 B MVjBdI9xfG:|aYOgRZN{[Xl? NFP3N2YzOM7:TR?= M{[2VlJp NXPvVGhHTE2VTx?= NVrWSZht[myxY3vzJIFvfGlvQ1S4NEBidmRiYX70bU1ETDh4IHHueIljd2S7LXnu[JVk\WRiYYDvdJRwe2m| NVTNU3NYOjRyMEi2Nlg>
CNE1 NG\w[FFCeG:ydH;zbZMhSXO|YYm= M1fPclIx|ryP MYW0PIg> M{\Nb4Jtd2OtczDMT{1CNWmwZIXj[YQh[XCxcITvd4l{ NXS3R2duOjN7OEWwNlk>
CNE2 NXixVZlISXCxcITvd4l{KEG|c3H5 NF;FOVgzOM7:TR?= M2\zPFQ5cA>? Ml;GZoxw[2u|IFzLMWEucW6mdXPl[EBieG:ydH;zbZM> M4LjN|I{QTh3MEK5
HL-60 NFPDOXpCeG:ydH;zbZMhSXO|YYm= Mm\SOVDDvU1? NITQR3MycA>? MlzjSG1UVw>? NH3vUlhqdmirYnn0d{BieG:ydH;zbZMhcW6mdXPl[EBjgSCEQUG0OS=> MYeyN|k1QDd3MR?=
L929 M{fDfmFxd3C2b4Ppd{BCe3OjeR?= NUD6bVNsOS5{NfMAl|XDqM7:TdMg M1fycFI1cA>? MWrheYdu\W62czDUUmbPuS2rbnT1Z4VlKG6nY4LvdJRwe2m|IHHu[EBifXSxcHjh[5k> NUTPPHVkOjN7NEG3Olk>
Jurkat M{i4V2NmdGxiVnnhZoltcXS7IFHzd4F6 M2XydFLPxE1? M2\qcFRp NHvWUpBz\X[ncoPld{Boem:5dHigbY5pcWKrdHnvckBidmRizsKtZ4F1\W6rbjDk[YNz\WG|ZTDifUBJWy2DU1G= M1rVdlI{QDl4ME[x
RAW264.7  MV7BdI9xfG:|aYOgRZN{[Xl? M1HuNVExKM7:TR?= NFHt[WUzPGh? NEThbFll\WO{ZXHz[ZMhfGinIHHwc5B1d3OrczDpcoR2[2WmIHL5JGdC M2\obVI{QDJyMkCz
A431  NGLwcpFMcW6jc3WgRZN{[Xl? NFyybVQ1OM7:TR?= NEnFT2UzcA>? M{TlToJtd2OtczDmbZNmfGmwLXnu[JVk\WRiY3zlZZZi\2Vib3[gZ4F{eGG|ZYOgZY5lKFCDUmC= NWDiR3J{OjN6MECwOVg>
Jurkat MnziR4VtdCCYaXHibYxqfHliQYPzZZk> NUL2T5YzOjVvMUCw{txO Ml;hOog> MlnYbY5pcWKrdIOgfk1HSS2FTVutbY5lfWOnZDDj[YxtKGSnYYTo NEm5bmUzOzl|M{WzNi=>
COS-7  M4LnV2Z2dmO2aX;uJGF{e2G7 MnTUOVDDvU1? MYeyOIg> MUDh[oZm[3S|IITo[UBxem:lZYPzbY5oKG:oIFHUUlF{KHerdHigdI9tgVFidILhZ5R{ Mlj1NlM6OzN{MEi=
CAL27 Mki1RZBweHSxc3nzJGF{e2G7 MXuxNEDPxE1? NIfmbIkzcA>? M4DBfJN2eHC{ZYPz[ZMhS3W{LV7Qd{1z\WS3Y3XkJJZq[WKrbHn0fUBjgSC3cDD0c{A6OCV? MmHPNlM6OTd|OU[=
THP-1  MnX0RZBweHSxc3nzJGF{e2G7 NH61cJQyOC13MN88US=> MnHXNog> Ml3LbY5pcWKrdIOgZZBweHSxc3nzJIlv\HWlZXSgZpkhfHKrcITvcIll\Q>? NWT1eo91OjN7MECyPVk>
K562 NWjN[nc2SXCxcITvd4l{KEG|c3H5 MorSNlDPxE1? M4DMPVQ5cA>? MlvPbY5pcWKrdIOgZZBweHSxc3nzJIlv\HWlZXSgZpkhPC2PVR?= NEjyfW4zOzh5NkiyOi=>
HL-60 MVXBdI9xfG:|aYOgRZN{[Xl? NYKxSm1vOTByzszN NITIPGczPGh? MnzrbY5pcWKrdIOgZZBweHSxc3nzJIlv\HWlZXSgZpkh[WKrZYThcoUh\Gm2ZYLw[Y5me8Li NWThcoJ1OjN6NkW3O|g>
HeLa  MoXoRZBweHSxc3nzJGF{e2G7 MYeyNO69VQ>? M1:5RVJp NETBepNqdmirYnn0d{BFVU2SIHnu[JVk\WRiYYDvdJRwe2m| MmXXNlM5PjN7Nk[=
U251 M2X0OWFxd3C2b4Ppd{BCe3OjeR?= NEnXdXEzOM7:TR?= MVOyOIg> MnjMbY5pcWKrdIOgZ4F{fGmlaX6gbY5lfWOnZDDHNk9OKHCqYYPlJIFzemW|dDDhcoQh[XCxcITvd4l{ M1LNT|I{QDF4OEG2
HL-60 NIrXdIpCeG:ydH;zbZMhSXO|YYm= NYHrS3FiPTEEtV2= MnPLOIg> NHn5e5VjdG:la4OgeIhmKGOuZXH2ZYdmKG:oIHPhd5Bie2VvMzygMVktKGGwZDDQRXJRKGmwZIXj[YQh[nliNoO= MWKyN|gxPDdyNh?=
Ec-109 MVLBdI9xfG:|aYOgRZN{[Xl? MV6xNEDPxE1? NFnobGI1QGh? Mnf2doVxemW|c3XzJHBGNW2nZHnheIVlKEWlLUGwPUBk\WyuIHHwc5B1d3Orcx?= M1f3dVI{Pzh{NkSx
RKO NHH5dldE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NGrFVGIyOCEQvF2= Mn3TNlRp MWnpcohq[mm2czD0bIUh\GWlcnXhd4Uhd2ZiY3XscEB3cWGkaXzpeJkh[2G3c3XkJIJ6KESDQh?= MnfYNlM4PThyNkS=
T98G NVHvVIszS2WubDDWbYFjcWyrdImgRZN{[Xl? MYWxMVExOM7:TR?= MmPSNlRp MoLIbY1xem:4ZYOgZ4VtdCC4aXHibYxqfHliY3;0doVifG2nboSge4l1cCCWUx?= MWmyN|c3QTJ5NR?=
Jurkat MmfER4VtdCCYaXHibYxqfHliQYPzZZk> MkX6NVAxNTJyMN88US=> M4fnbVI1cA>? NV\KTmZPcW6qaXLpeJMhUGGDNDDpcoR2[2W|IHHwc5B1d3OrczDk[ZBmdmSnboSgc4Yh[2:wY3XueJJifGmxbtMg MmP0NlM4OzJ2OEG=
Molt-3  M1HEN2Fxd3C2b4Ppd{BCe3OjeR?= NIHLWGE2OM7:TR?= NEHUWpMzcA>? MnrPdoVlfWOnczDt[YxifG:waX6tbY5lfWOnZDDhdI9xfG:|aYO= NFT1N2IzOzd{NUCxNy=>
hMSC12 NUPqc2trSXCxcITvd4l{KEG|c3H5 MlmzNVAx|ryP NXPnWYFoPGR? M2iyfYlvcGmkaYTzJI9{fGWxZ3XubYMh[3WudIXy[U1qdmS3Y3XkJINmdGxiZHXheIgh[W6mIHPhcINq\mmlYYTpc44> M3TucFI{PjV5OEKy
HM7  MX7BdI9xfG:|aYOgRZN{[Xl? NXXO[WNOOjEQvF5CpC=> MXSxbC=> M3ThXoJtd2OtczDhdIlkfWyjcnXuJGEh[WOndHH0[U1qdmS3Y3XkJINie3Cjc3WtN{Bi[3SrdnH0bY9vKGGwZDDQRXJRKGOuZXH2ZYdm NH3lNZkzOzV6M{SxNi=>
Hep-2  MonmRZBweHSxc3nzJGF{e2G7 NUHwclRTOjEQvF5CpC=> Mn;CNlRp MkjWSG1UVw>? M3:0VYFtdGW4aXH0[ZMhfGinIHTlZ5Jm[XOnIH;mJINmdGxidnnhZoltcXS7IHnu[JVk\WRiYomgd4ltcWKrbnnu MUOyN|U5ODB|Mh?=
HSCs M4\zTmFxd3C2b4Ppd{BCe3OjeR?= MYq1NO69VQ>? MYCyOIg> M{Cy[WROW09? MlXIbY5pcWKrdIOgcoltd3SrbnniMYlv\HWlZXSgSG5CKGSjbXHn[UBqdmSrY3H0[YQh[nliUFHSVEBkdGWjdnHn[S=> NEHGNW4zOzR7OUi3OC=>
HL-60  M{DjbWN6fG:2b4jpZ4l1gSCDc4PhfS=> NEDub4wzOM7:TdMg M1PrV|I1cA>? M3HLWJJm\HWlZYOgeIhmKGO7dH;0c5hq[yCnZn\lZ5Qhd2ZiRYL5OS=> NInTXGwzOzR7NES4NC=>
HA Mn7IRZBweHSxc3nzJGF{e2G7 NEfzUoM2OM7:TR?= NYHvcWR2OjSq NI\jPHl{fXCycnXzd4V{KHSqZTDjcIVifmGpZTDv[kBRSVKSIHHu[EBk[XOyYYPlMVMtKC15LDDhcoQhNTliaX7keYNm\CCkeTDic5J1\XqxbXniM3NCUEF? MUSyN|Q4PTl3Nh?=
C666-1 NHnQVYpCeG:ydH;zbZMhSXO|YYm= NIjqUpc2OM7:TR?= MoOxNlRp MljXd5VxeHKnc4Pld{B1cGViY3zlZZZi\2Vib3[gVGFTWCCjbnSgZ4F{eGG|ZT2zMEAuPyxiYX7kJE06KGmwZIXj[YQh[nliYn;yeIV7d22rYj;TRWhC NV3NNZBTOjN2N{W5OVY>
Hepa1-6 MnrNRZBweHSxc3nzJGF{e2G7 NVrMT|JWPTEQvF2= NEKxPYgzcA>? MnizbY5pcWKrdIOgZ5Vz[3WvaX6gZY5lKHKnc4\ldoF1em:uLXnu[JVk\WRiYYDvdJRwe2m| NX33dpZVOjN2NE[3OVM>
PLC/PRF/5c NFLjSW9CeG:ydH;zbZMhSXO|YYm= MXm1NO69VQ>? NU\PV5hROWh? NUTPb4lUeHKndnXueJMh[XCxcITvd4l{KHS{aXfn[ZJm\CCkeTDDTW4> MWmyN|Q{QDh{NB?=
HCT116 NYPZNm1[SXCxcITvd4l{KEG|c3H5 M3fiUFExOM7:TR?= M{LFNVEvPWh? NEO1ZmlqdmirYnn0d{BQey2rbnT1Z4VlKGOnbHyg[IVifGh? MoCzNlM4PDR|NUO=
HCEC M4[xWmZ2dmO2aX;uJGF{e2G7 MmXwOVDPxE1? NFjrZ|U4Omh? M{P6SGROW09? NW[5dXBsemW|dH;y[ZMhd2ZidHjlJI5wem2jbDDIR2VEKHCqZX7veJlx\Q>? MmP2NlM4PDJyMUG=
Primary rat cerebral cortical neurons NELqeY9CeG:ydH;zbZMhSXO|YYm= M1[1cVExOM7:TR?= MUexbC=> M3TuVJBz\X[nboTzJGNlNWmwZIXj[YQh[XCxcITvd4l{KGGwZDDj[YxtKGSnYYTo MXqyN|c1OTNzNx?=
MDA-MB-231  MlzJRZBweHSxc3nzJGF{e2G7 NY\QT5BrOjYQvF2= NGfZeVczPGh? MkDtZYJzd2ejdHXzJIN6fG:2b4jpZ4l1gSCjbnSgZ4xm[X[jZ3Wgc4Yh[2G|cHHz[U0{KGGwZDDQRXJRKGmwZIXj[YQh[nliUnez NIHVRYszPTN|N{W0OC=>
NLRP3-Tet-on-MC/9  M1XVWmFxd3C2b4Ppd{BCe3OjeR?= Mk\PNVAuPDEQvF2= MV:xNog> NV;l[VB{[XS2ZX71ZZRmeyC2aHWgZ4VtdCCmZXH0bEBk[XW|ZXSgZpkhS0GSUz3hd5Nw[2mjdHXkJG5NWlB|IH31eIFvfHNiaX6geIhmKFSndD3vckB{gXO2ZX2= NWTpZ5Q2OjN5MEOzPFk>
KNS42  MUDBdI9xfG:|aYOgRZN{[Xl? MWK1NO69VQ>? MV[xbC=> NELocoZz\WS3Y3XzJINmdGxiZHXheIgh[W6mIHPvcZBt\XSnbImgZYJwdGm|aHXkJINie3Cjc3WgN{84KGGldHn2bZR6KGmwIILld5BwdnOnIITvJGFDXC1{NkOvNmRIN22ndH\vdo1qdiClb33ibY5ifGmxbh?= MUSyN|Y6OTF2NR?=
MCF-7  M1flbmFxd3C2b4Ppd{BCe3OjeR?= NIW1d|kzOM7:TdMg Mn7mO|Jp NIXSW21qdmirYnn0d{BmeXWxbD2gZY5lKDRvT1jUMY1m\GmjdHXkJIFxd3C2b4Ppdy=> MW[yN|Y4PTZ2Mx?=
hCMEC/D3  NIWxZ3NCeG:ydH;zbZMhSXO|YYm= NX\mb2tCOjYQvF2= Ml3wO|Jp NYnEO49GemWmdXPld{BNfHiDIHnu[JVk\WRiYYDvdJRwe2m| NFvQbokzOzZ4NUG5PC=>
Jurkat M{H2O2Fxd3C2b4Ppd{BCe3OjeR?= NIXaVFIyOi53LUWw{txO MXmxbC=> NWPqRnBo\G:|ZTDk[ZBmdmSnboTsfUB{fXCycnXzd4V{KFOSSD3pcoR2[2WmIGDhdk01KGOuZXH2ZYdmNCCSQWLQJINt\WG4YXflMEBFVkFiZoLh[41mdnSjdHnvckwh[W6mIHzvd5Mhd2ZidnnhZoltcXS7 M1rITVI{PDR{OUe2
CNE-1 MoWzRZBweHSxc3nzJGF{e2G7 M3WwcFIx|ryPwrC= M3fUOFI1cA>? MYjpcohq[mm2czDSRWQxODFvaX7keYNm\CClZXzsJIRm[XSq MYKyN|QzPjh3MB?=
HONE-1 NI[5SWFCeG:ydH;zbZMhSXO|YYm= MoTMNlDPxE4EoB?= Mo\mNlRp MVfpcohq[mm2czDSRWQxODFvaX7keYNm\CClZXzsJIRm[XSq MXeyN|QzPjh3MB?=
astrocytes cell MYnBdI9xfG:|aYOgRZN{[Xl? NEPjSHk1OM7:TR?= NYKzSHlyPmh? MlrTdoVlfWOnczDlZZJtgSCjcH;weI9{cXNiaX7keYNm\CCkeTDzeIF2em:|cH;ybY5m NXPNTXNTOjN2MUG3O|g>
U-937 MXPBdI9xfG:|aYOgRZN{[Xl? NFXUWHIyOM7:TR?= M1HSVlMxdWmw MlThdJJmfmWwdIOgWG5HNWmwZIXj[YQhdmWlcn;weI9{cXN? M{P0TVI{PDFyN{S4
MDA-MB-231 NHjWXY5CeG:ydH;zbZMhSXO|YYm= MmPJNVAx|ryP NXzLUXNEOWh? NXLLO4Y4cW6qaXLpeJMhe2Wwc3n0bZpifGmxbjD0c{BVWkGLTDD1dI9vKE2WRFig[I94di2{ZXf1cIF1cW:w NYjk[m9lOjN2MEi0Nlk>
HeLa  MmfTRZBweHSxc3nzJGF{e2G7 NHjFbmEyODEQvF2= NHzpU|UzcA>? NInZcGZjdG:la4OgTnJUNTF3IFnu[JVk\XNiQYDvdJRwfGmlIFPlcIwhTGWjdHi= NEj0bI0zOzN2NEC0OS=>
Ec109 MVTBdI9xfG:|aYOgRZN{[Xl? M3XhT|Ex|ryP M1\lT|Zp MUnicI9kc3NiYYDvdJRwfGmlIHPvcYJqdmG2aX;uJI9nKFSjdD3TcYFkVjdiYX7kJJJi\GmjdHnvci=> MlvFNlM{Ozh3Nki=
H460  NWe4OWQ6SXCxcITvd4l{KEG|c3H5 NIrpcWIyOM7:TR?= M{LZW|Zp MkjMZoxw[2u|IHHwc5B1d3SrYzDjc41jcW6jdHnvckBw\iCWYYStV41i[055IHHu[EBz[WSrYYTpc44> NH7UWlQzOzN|OEW2PC=>
HeLa  Mn3ORZBweHSxc3nzJGF{e2G7 NUjPW2pWPTEQvF2= MWGxMlVp MXLhZpJw\2G2ZYRCpGNpdGGveXTpZU1qdmS3Y3XkJIFxd3C2b4Ppdy=> M4DzclI{OzB|OEC0
SK-HEP1 NWnBTHptSXCxcITvd4l{KEG|c3H5 MlnBNVAx|ryP NWXrWG1POWh? NYjnZ3RPcW6qaXLpeJMhS3KWMTDhZ5RqfmG2ZXSgZ4F{eGG|ZT2zMEAuPyxiLUisJE06NCCjbnSgdI9tgSiDRGCtdoljd3OnKTDwc4x6dWW{YYPl MkO2NlM{ODJ4NUC=
QGY7701 M2DDNWFxd3C2b4Ppd{BCe3OjeR?= MVOyOe69VQ>? M2G3NVEvPWh? NHG1fY1qdmirYnn0d{Bi[2O3bYXsZZRqd25ib3[gd5VjNUdzIIDoZZNmKGmwZIXj[YQh[nliRF;YJEsheXWncnPleIlv MWiyN|I1ODB4MR?=
HepG2 MUjBdI9xfG:|aYOgRZN{[Xl? NFzxNIQzOM7:TR?= NELyS28{OG2rbh?= NEnEb41qdmirYnn0d{B1cGViZX7oZY5k\WRiY3XscEBl\WG2aDDifUBkd22kaX7l[EB1emWjdH3lcpQhd2ZiYYDp[4VvcW5iYX7kJHRTSUmO MWSyN|IzPDJ|OR?=
U87  M3WzSmFxd3C2b4Ppd{BCe3OjeR?= MVGyOe69VQ>? NFK0SmczcA>? M4DOfYRm[3KnYYPld{Bqe2:uaYH1bZJqfGmpZX7pckApUVOOKT3pcoR2[2WmIHHwc5B1d3SrYzDj[YxtKGSnYYToMEBjfXRibn;0JI5m[3KxdHnjJINmdGxiZHXheIg> MWmyN|IzQTZ{Nh?=
HSC-2 MWXBdI9xfG:|aYOgRZN{[Xl? NGnvN40zPS93MN88US=> MoPCNYg> M4XZbIlvcGmkaYTzJHNPNTN6LXnu[JVk\WRiY4n0c5RwgGmlaYT5 NFH0[Y4zOzF3NUK0PC=>
HSC-4 MnrtRZBweHSxc3nzJGF{e2G7 M3zOVVI2NzVyzszN NWT5WYRGOWh? NEfsTYtqdmirYnn0d{BUVi1|OD3pcoR2[2WmIHP5eI91d3irY3n0fS=> NXPmfploOjNzNUWyOFg>
CL-1 NGPrdFRCeG:ydH;zbZMhSXO|YYm= NFj5OIIzOM7:TR?= MY[xbC=> NIPTeGVjdG:la4OgU3A1PDliaX7keYNm\CClZXzsJIRm[XSq NUP0S|dxOjNzM{G3PFI>
MEL NGPFdIRCeG:ydH;zbZMhSXO|YYm= Mn;6NlDPxE1? MVeyOIg> MmjPSG1UVw>? NV;z[3M6cW2yYXny[ZMhWDK[Nz3pcoR2[2WmIF3FUEBk\WyuIHHwc5B1d3Orcx?= MV6yN|AyPDh6Nx?=
Bel-7402  MlXKR4F{eGG|ZTDBZ5RqfmG2aX;uJGF{e2G7 M1rkblUx|ryP MoO4Nog> M4W1fIlvcGmkaYTzJHBETS2rbnT1Z4VlKGGwb3nrbZM> MUiyN|AxQDd2Mh?=
Eca-109 NEHrbHZCeG:ydH;zbZMhSXO|YYm= M2TYOFI2|ryP MmTDN|BucW5? M3vNfolvcGmkaYTzJGJLNUJzMT3pcoR2[2WmIHPlcIwh\GWjdHi= NW\jdJZlOjNyN{[5Olc>
MEL MVzBdI9xfG:|aYOgRZN{[Xl? M4LiWVIx|ryP NVva[mljOWh? NVvsXnVNTE2VTx?= MX\pcZBicXKnczDQNng4NWmwZIXj[YQhVUWOIHPlcIwh[XCxcITvd4l{ MoXGNlMxOTR6OEe=
Bel-7402  MlyxRZBweHSxc3nzJGF{e2G7 M{HRNlUx|ryP NH\pfWgzcA>? M2fXOIlvcGmkaYTzJHBETS2rbnT1Z4VlKGGwb3nrbZM> MmLZNlMxODh5NEK=
L929 NXTnW4NFTnWwY4Tpc44hSXO|YYm= M{D4UFIvPc7:TR?= NUDDTVFCOWh? MW\pcoNz\WG|ZYOgVmlROSCneIDy[ZN{cW:wIHHu[EBmgGGlZYLiZZRm\CCWTldOtU1qdmS3Y3XkJI1qfG:laH;u[JJq[WxiZInz[pVv[3Srb36gZY5lKFKRUzDwdo9lfWO2aX;u NW\UXYg6OjNyMEC1NVg>
RCC  NGPvUmZE\WyuIG\pZYJqdGm2eTDBd5NigQ>? M1nDNVExOM7:TR?= NUixOnVzOjSq M{\FepJm[2:4ZYLld{B1cGVidnnhZoltcXS7IH;mJINmdGy|IHX4dI9{\WRidH:gNVVlNVCJSkK= NYDxc2NxOjJ7OUG0PVQ>
NB2a/d1 NFW4TGlCeG:ydH;zbZMhSXO|YYm= MlHPNVAx|ryP NHroVWY4Omh? NWnlVFFS[XS2ZX71ZZRmeyC|dHH1do9{eG:{aX7lMYlv\HWlZXSgZ4F{eGG|ZTDhZ5Rqfmm2eTygVGFTWCxiYX7kJJRifSClbHXheoFo\Q>? NWnvWXYxOjJ7OEi1OFE>
T cell NXfwXGo1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml71NlUuOTByzszN NVnTSY9COjSq NHvkfY1ld3OnLXTldIVv\GWwdHz5JIlvcGmkaYTl[EBVKGOnbHygdJJwdGmoZYLheIlwdiCvZXTpZZRm\CC2aILveYdpKHSqZTDjc{1{fGmvdXzheIlwdiC5aYToJIFvfGlvQ1SzJIFv\CCjboTpMWNFOjh? M3jrXVIzQTh{NUO4
K562 MVnBdI9xfG:|aYOgRZN{[Xl? NUPtcVlXOTByzszN MYSxbC=> MlrzZoxw[2u|IFHico9j[X[rc3P1ceKhTi2rbnT1Z4VlKGGyb4D0c5Nqew>? MUCyNlk4OjN5Mh?=
Jurkat  NUWwbWVlSXCxcITvd4l{KEG|c3H5 MYe0NO69VQ>? NWLKemN{OWh? MlnLZYJwdGm|aHXzJGZie0xvaX7keYNm\CClYYPwZZNmKGGldHn2ZZRqd25iYX7kJINmdGxiZHXheIg> MkTONlI6PDJ5M{i=
BGC-823 M{HEXmFxd3C2b4Ppd{BCe3OjeR?= M1jGcFExOM7:TR?= NVLmVVhZOWh? M4mxR5BienSrYXzsfUBz\XOldXXzJINmdGy|IHHnZYlve3RiZHHtZYdmKG:oIHThbYR7\Wmw NYPWTmFjOjJ7Mk[1OFU>
Hep3B M4D4UGFxd3C2b4Ppd{BCe3OjeR?= MYK1NO69VQ>? MWqxbC=> NFGxOnNjdG:la4OgZZBweHSxc3nzJIlv\HWlZXSgZpkhUEWJQ4O= NVvJeYdkOjJ7MkOxOVQ>
LLC-PK1 M{XzU2Fxd3C2b4Ppd{BCe3OjeR?= NHrxXJYzOM7:TR?= M{m0VlFp M2jSPZBz\X[nboTzJINqe3CuYYTpck1qdmS3Y3XkJIRm\3KjZHH0bY9vKG:oIFH0[|UtKGKnY3zpck0yNCCjbnSgRZRoOTJicILveIVqdnN? M4rlW|IzQDl4MEO3
A549 MUfBdI9xfG:|aYOgRZN{[Xl? MoHmOVDPxE1? MlXjNYg> NWiwRpF1[myxY3vzJJRp\SCEQVmtbY5lfWOnZDDhdI9xfG:|aYRCpC=> Ml;KNlI5QDd{MUW=
SGC-7901  Mn;XRZBweHSxc3nzJGF{e2G7 NWTUdYhoOTEQvF2= NHLOUGszPGh? NW\XbY0{cW6qaXLpeJMh|rJuzsKt[Ilu\XSqeXzhZ5J6dHOqaXvvcolvNWmwZIXj[YQh[XCxcITvd4l{yqB? M2DqXFIzQDR6NUm3
DM6 M2TkVGFxd3C2b4Ppd{BCe3OjeR?= NWqyU5pWOTByzszN MmPjO|Jp NWfDSHFu[myxY3vzJIJwfGhiRULGMVEh[W6mIFWySpRzNW2nZHnheIVlKGO7dH;0c5hq[2m2eR?= M4jydVIzQDJ3M{K4
MCF-7, MDA-MB-468, Caco-2 NWLwSIJtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXK1NO69VQ>? MWO0PIg> MljGbY5pcWKrdIOgeIhmKGOnbHyg[5Jwf3SqIHnubIljcXSrb36gbY5lfWOnZDDifUB{[XCxbnnu MYeyNlgxODl4OB?=
A2750  MlfDRZBweHSxc3nzJGF{e2G7 NUezT4Z4OjEQvF2= NV36RphkOmh? M4C3WmROW09? MYHicI9kc3NiY3HzdIF{\SClbHXheoFo\SCmdYLpcochcGWuZX7hcIlvKHS{ZXH0cYVvfCCjbnSgdoVlfWOnczDheZRweGijZ3njJINmdGxiZHXheIg> NFK1co4zOjd6NEO2Ny=>
U87  MmrVRZBweHSxc3nzJGF{e2G7 MoH6NlDPxE1? MVWyOIg> NELSV3hz\WS3Y3XzJJRp\SCjcH;weI9{cXNicnH0[UBqdmS3Y3XkJIJ6KFCOQVK= MWSyNlc4QDd6MB?=
HT1080 NX\TZpgzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MY[1NO69VQ>? NGPGeHE4\A>? MWTpcohq[mm2czD0bIUh[2WubDDndo94fGhiaX7obYJqfGmxbjDjZZV{\WRiYomgZ49u[mmwZXSgeJJm[XSvZX70JI9nKESFQTDhcoQhV02S NU[zTmxEOjJ5NEC5PFQ>
A549  M2XlTWFxd3C2b4Ppd{BCe3OjeR?= NXjJSG1JPTEQvF2= NE\RRVUzcA>? M1r4OZBienSrYXzsfUBl\WO{ZXHz[ZMhe2:maYXtJJNmdGWwaYTlMYlv\HWlZXSgZZBweHSxc3nz NUC5bnpLOjJ5MkG4NFQ>
Primary OPC NHrWd5VCeG:ydH;zbZMhSXO|YYm= NV:0fW4yOc7:TR?= NVT1cIhwPmhxMkTo MUjy[YR2[2W|IITo[UBx\XKlZX70ZYdmKG:oIHPlcIx{KGmwIHXhdox6NSCjbnSgcIF1\S2jcH;weI9{cXNxbnXjdo9{cXN? NILsOZQzOjdyN{O4OS=>
PMNs MUDBdI9xfG:|aYOgRZN{[Xl? MVm0NO69VQ>? M1\XUVZp M2DLR2ROW09? MV\y[ZZmenOnZDD0bIUh[W2xdX70JI9nKGOuZXH2[YQh[2G|cHHz[U0{KHSxIH7lZZIhfmWqaXPs[UBt\X[nbIO= MYSyNlY6OjV5Nx?=
A549  NXL6Zo1ySXCxcITvd4l{KEG|c3H5 MmXSOVDPxE1? NIPRN4MycA>? MYHwdoV3\W62czDhdI9xfG:|aYOgbY5lfWOnZDDifUBD[W:qdX;zbYRmKEl? M4LPWVIzPjh5NkO1
AGS MmjBRZBweHSxc3nzJGF{e2G7 MoL6NlDPxE1? NEXrfVcyOmh? M3v5c4lvcGmkaYTzJJRp\SCjY4TpeoF1cW:wIH;mJJBzdy2lYYPwZZNmNTNiaX6gdoV{eG:wc3WgeI8hfGinIFX0U2FkKG[{YXP0bY9v MUCyNlY5PzN7OB?=
shC9  NX;VNZN{SXCxcITvd4l{KEG|c3H5 NWPCWFdYOTEQvF2= NHXtcnQyPmh? Ml;HZox2dnS|IGPITEBmgHC{ZYPzbY9vKGmwIIPoR|kh[2WubIOg[Zhxd3OnZDD0c{BmcXSqZYKgVGEhd3JiTGDD MXiyNlY1OTB7NB?=
primary MEFs NFjLW5BHfW6ldHnvckBCe3OjeR?= M{\MfFEzcA>? MoTRxsBqdmO{ZXHz[ZMh\XSxcH;zbYRmNWmwZIXj[YQhdWm2b3Poc45lemmjbDDt[Y1jemGwZTDk[ZBwdGG{aYrheIlwdg>? M1TuTVIzPjF|N{[3
3T9 MEFs M{Ox[mZ2dmO2aX;uJGF{e2G7 M3PlclE3cA>? M2THS4lv[3KnYYPld{BkgXSxY3jyc41mKGNicnXs[YF{\SCjZoTldkBmfG:yb4Pp[IUufHKnYYTt[Y51 NILncGUzOjZzM{e2Oy=>
3T9 MEFs NH7vcI1HfW6ldHnvckBCe3OjeR?= NE\P[XoyQGh? MVT1dJJm\3WuYYTld{Bqdmm2aXH0c5Ih[2G|cHHz[U06KGK3dDDkc5dvemWpdXzheIV{KGWoZnXjeI9zKGOjc4Dhd4V{KGGodHXyJIV1d3Cxc3nk[UB1emWjdH3lcpQ> MnLrNlI3OTN5Nke=
MDA-MB-231  NY\i[5FNSXCxcITvd4l{KEG|c3H5 MUeyNO69VQ>? MXi0[C=> NI[5c2Jz\WS3Y3XzJJRp\SClZXzsJIFxd3C2b4Ppd{BqdmS3Y3XkJIJ6KG2ndH\vdo1qdiC2cnXheI1mdnRid3HzJJNq\26rZnnjZY51dHl? NF3xR2wzOjV7M{S0NS=>
C6  NWHSbFNCSXCxcITvd4l{KEG|c3H5 MlTJNVDPxE1? NFnwNpgzPGh? MWjicI9kc3NidHjlJJN2eHC{ZYPzbZZmKGWoZnXjeEBw\iC2aHWgdIVxfGmmZTDvckB3cWGkaXzpeJk> Mlu5NlI2QDh7OEC=
HL-60  M2P5bGFxd3C2b4Ppd{BCe3OjeR?= M1Sw[VExOM7:TR?= MXKyOIg> NXL0enFEcW6qaXLpeJMhfGinIHPlcIwh[XCxcITvd4l{KHOnbHXjeIVlKChtKT3t[Y51cHmuIN8yMUgy6obUNjmt[IlodHWlb4D5doFvd3OrZHZCpFU> NFfK[ZczOjV2Nk[2PS=>
HL-60 NEXkUG5CeG:ydH;zbZMhSXO|YYm= NH7rfmQyOC16MN88US=> NHLie5k1cA>? M3z5UYlvcGmkaYTzJHRIUFFvaX7keYNm\CClZXzsJIFxd3C2b4Ppd:Kh MlPxNlI2OjN{Mkm=
BCC NETXVHZCeG:ydH;zbZMhSXO|YYm= NXThfXR6PTEQvF2= NGPOXWwycA>? NXXDVGlEcW6qaXLpeJMhTEGWUz3t[YRq[XSnZDDndo94fGhiaX7obYJqfGmxbh?= NVi0emxXOjJ3MUm0N|Y>
RAW 264.7 M4ewfWFxd3C2b4Ppd{BCe3OjeR?= NHGyeVU2OC9zMEFOwG0> NYn0W|lvOWh? M3nLRYNwdmOnboTyZZRqd25vZHXw[Y5l\W62IHnubIljcXS|IFTPUk1qdmS3Y3XkJJJTVkFiY3zlZZZi\2V? NFz1V4YzOjR7MUSyOi=>
K562 M3;LeWFxd3C2b4Ppd{BCe3OjeR?= NFftbYEzPc7:TR?= NUi5fZNsOmh? M4\Mb5Bz\X[nboTzJIFxd3C2b4Ppd{BqdmS3Y3XkJIJ6KGOxLYTy[YF1dWWwdDD3bZRpKGGvdYLlcpNqdiCJIHHu[EBVWkGLTB?= MUWyNlQ5Ozd5Nx?=
SGC-7901 NYPSVXJSSXCxcITvd4l{KEG|c3H5 NHThSmkzOCEQvF5CpC=> M2TqSVJp MV\heJRmdnWjdHXzJGgzVzMEoH;yJHRPTiEQsT3pcoR2[2WmIHPlcIwh[XCxcITvd4l{KGG|IIflcIwh[XNiY3HzdIF{\S1|IHHjeIl3cXS7wrC= NYT3U5NZOjJ2N{G1PFk>
PC3 MUfBdI9xfG:|aYOgRZN{[Xl? M{fJXFEx|ryP MUi0bC=> NXziTXNx[2:3boTldpMh\myjdn;jc5hq\C2rbnT1Z4VlKGOjc4Dhd4UuemWuYYTl[EBieG:ydH;zbZM> MlLpNlI1PzF7N{S=
SMMC-7721 MknqRZBweHSxc3nzJGF{e2G7 NXv6SVRMPTEQvF2= MY[0PIg> MmLtZZR1\W63YYTld{BwXFJvaX7keYNm\CCjcH;weI9{cXN? M4T4TlIzPDZ3OEOz
HeLa  NETjfmlCeG:ydH;zbZMhSXO|YYm= MYG1NOKh|ryP MYi0M|hp NFntVpdqdmirYnn0d{BUXFNvaX7keYNm\CCuYYTlMZBp[XOnIHHwc5B1d3SrYzDleoVvfHN? M13WWlIzPDZyNUC0
HeLa  Ml:0RZBweHSxc3nzJGF{e2G7 NEXoW4w2OMLizszN M3vZZVFp NH;TUXZ{fXCycnXzd4V{KHSqZTDGVmFRNWmwZIXj[YQh[WOldX31cIF1cW:wIH;mJIFvdmW6aX6gWkBxd3OrdHn2[UBk\Wyucx?= NUT5dZo2OjJ2NEm0OFA>
T47D  M3LmdWFxd3C2b4Ppd{BCe3OjeR?= MnTZNVAx|ryP NU\xdlBMOWh? MWricI9kc3NidHjlJIdmdmW{YYTpc44hd2ZiRT3jZYQwS1SIMjDifUBUXFN? Ml3hNlI1ODFzNki=
HeLa  NEnvNYNCeG:ydH;zbZMhSXO|YYm= MYSzNO69VQ>? Ml;zOIg> NYH4W40{yqCrbnPy[YF{\XNidHjlJIdmdmW{YXygZ4VtdCC4aXHibYxqfHliNEigbEBi\nSncjDwbI91d2S7bnHtbYMhfHKnYYTt[Y51yqB? MWCyNlM6PDJ2OB?=
HCC NG\2UIpCeG:ydH;zbZMhSXO|YYm= MXqyNEDPxE4EoB?= Mo\rNog> Ml3NZZR1\W63YYTld{B1cGViRFjBJIlv\HWlZXSgZYN1cX[jdHnvckBw\iCSQWLQ NIH3b4gzOjN2MkezNi=>
mESCs M1Xud2Fxd3C2b4Ppd{BCe3OjeR?= NUGxNoxvOi53zszN NECxRlYzcA>? M2HTXIlvcGmkaYTzJJRp\SCQYV[tcYVlcWG2ZXSgZ4F{eGG|ZTDhZ5RqfmG2aX;u NVTZbnBJOjJ{OEWyO|Q>
EMT-6  NIe4ZppEgXSxdH;4bYNqfHliQYPzZZk> NFjvWnMyODEQvF2= NEDiPJgycA>? M1:4VZBienSrYXzsfUBjdG:la3XkJINmdGxiZHXheIghcW6mdXPl[EBjgSC|aYLhcYV{cW6n NVH2XYxTOjJ{NUG5NlE>
MCF7 M1i4UmFxd3C2b4Ppd{BCe3OjeR?= MlexOVDDqM7:TR?= Mn;sNYg> M4fEOIlvcGmkaYTzJHBCKGGldHn2ZZRm\CClYYPwZZNmNTNuID25MEBidmRicH;sfUhCTFBvcnnic5NmMSCyb3z5cYVz[XOn NG\GdpczOjJ{M{O0OS=>
K562 M1:1cGFxd3C2b4Ppd{BCe3OjeR?= MkHMNlAh|ryPwrC= Mmn4OFhp M3:xS2ROW09? MWTicI9kc3NibHHwZZRqdmmkLXnu[JVk\WRiaX7obYJqfGmxbjDv[kB3cWGkaXzpeJkh[W6mIHHwc5B1d3OrczDpcoR2[3Srb36= NWnRbGExOjJ{MU[xOVg>
Molt4-hyg NVHHZ2VtSXCxcITvd4l{KEG|c3H5 NGrYWpEyOM7:TR?= NIXBZ|gxNjWq Mn\MZoxw[2u|IH\hdo5me2:uLXnu[JVk\WRiY3HzdIF{\S1|LXzpb4Uh[WO2aY\peJk> NULONG1NOjZ{N{W4NVE>
HeLa NUjGNYMxSXCxcITvd4l{KEG|c3H5 MkjzNVDPxE1? MUOwMlVp NEfTT5NqdmirYnn0d{BieG:ydH;zbZMhcW6mdXPl[EBjgSC2aHWgZ49u[mmwZXSgeJJm[XSvZX70JJdqfGhiZ3;tbZNqdiCQIHHu[EBVWkGLTB?= NGXCWHAzOjF5OU[2NS=>
Jurkat T NUjtT|doSXCxcITvd4l{KEG|c3H5 M2TTcVMx|ryP M37aelAvPWh? MkXmSG1UVw>? NHu3eZdjdG:la4OgeIhmKHqrcnHtMYlv\HWlZXSgZZBweHSxc3nz NHXw[28zOjF3OUi5PC=>
Neutrophil NFXaRohCeG:ydH;zbZMhSXO|YYm= MUKyNO69VQ>? M13nc|AvPWh? NFi1cYpifHSnboXheIV{KHSqZTDwdo8u[XCxcITveIlkKGWoZnXjeEBw\iCPYWKx NXyzOo9UOjZzOU[4OFQ>
HCT116 M1uzXWFxd3C2b4Ppd{BCe3OjeR?= NHrmXpA2OMLizszN M{LjPVJp NHSyNIdz\X[ncoPld{B{gW6ncnfpd5Rq[yCjcH;weI9{cXNiZX\m[YN1eyCxZjDj[Yxm[2:6aXKgZY5lKE6SQz2xOuKh NGLKb5UzOjF3OUe1Ni=>
MDA-MB-231  Mle3RZBweHSxc3nzJGF{e2G7 MYmyMlUuPy53zszN Ml71Nog> M2nzbolvcGmkaYTzJJRp\SClZXzsJIRm[XSqIH;mJG1FSS2PQj2yN|Eh[2WubIOgbY5lfWOnZDDifUBUTFRiaX6gZUBkd26lZX70doF1cW:wIHTldIVv\GWwdDDtZY5v\XJ? NVLze3p4OjJzMUW1NlY>
LNCaP Mlq5RZBweHSxc3nzJGF{e2G7 M4DsXlQx|ryP NGTzRYkzcA>? MmCxbY5pcWKrdIOgZpV1\WmwIHnu[JVk\WRiY3XscEBieG:ydH;zbZM> MlOxNlIyOTR5NkS=
MB231 NYDHW5ZPSXCxcITvd4l{KEG|c3H5 NWDweol{OTByzszN NVTacpQyOWh? M4K2WGROW09? M1nBVoFjem:pYYTld{B1cGViaX7keYN1cW:wIH;mJINmdGxiZHXheIgh[nliV1XFNUBqdmirYnn0bY9vNCCWUlHJUEB1emWjdH3lcpQtKGGwZDD0bIUh[2:vYnnuZZRqd25? NFHXNlkzOjFzMkm0NC=>
HCC38  MlnuRZBweHSxc3nzJGF{e2G7 M2TqO|ExOM7:TR?= NES5encycA>? MmHPSG1UVw>? M2XYRYFjem:pYYTld{B1cGViaX7keYN1cW:wIH;mJINmdGxiZHXheIgh[nliV1XFNUBqdmirYnn0bY9vNCCWUlHJUEB1emWjdH3lcpQtKGGwZDD0bIUh[2:vYnnuZZRqd25? Mlf1NlIyOTJ7NEC=
MDA-MB231 MVXBdI9xfG:|aYOgRZN{[Xl? NWPNZ|FvPTEEoN88US=> MWOyOIg> MnX0SG1UVw>? M121cYFjem:pYYTld{BkfXKldX3pck1qdmS3Y3XkJINmdGxiZHXheIg> MlewNlIyODF|M{W=
LNCaP M4O0NmFxd3C2b4Ppd{BCe3OjeR?= NHHlTmQ2OMLizszN NVzIOXYzOjSq NECyNpJFVVOR M2\td4Fjem:pYYTld{BkfXKldX3pck1qdmS3Y3XkJINmdGxiZHXheIg> MXiyNlExOTN|NR?=
HCT116 MU\BdI9xfG:|aYOgRZN{[Xl? NFqzcJo2OMLizszN MonGNlRp M3;Lc2ROW09? Mle3ZYJzd2ejdHXzJIN2emO3bXnuMYlv\HWlZXSgZ4VtdCCmZXH0bC=> MUCyNlExOTN|NR?=
Ishikawa  MlfwRZBweHSxc3nzJGF{e2G7 M3npV|I2|ryP M1T2UVI1cA>? M2PuSpJm\HWlZYOgZ4VtdCCmZXH0bEBidmRiYYDvdJRwe2m|IHnu[JVk\WRiYomgRoFnKEFz MV:yNlA5QDlzOB?=
 YD-8  NHTjZW5CeG:ydH;zbZMhSXO|YYm= NWXGWYVyOTByzszN MYCxbC=> MULpcohq[mm2czDQUGVQNWmwZIXj[YQh[XCxcITvd4l{ NYfGPXNHOjJyOE[xPFM>
eosinophil  M2PzdmFxd3C2b4Ppd{BCe3OjeR?= M1W1[|kx|ryP MVOyOIg> MVPpcohq[mm2czDhdI9xfG:|aYOgbY5lfWOnZDDifUBH[XNiYX70bYJw\HoEoB?= MVeyNlA4QTN|NB?=
L929 NWPJfo04T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF7tU2czNjYQvF2= MkXxNlRp NELPcVdqdmirYnn0d{B1cGViZYjwdoV{e2mxbjDv[kBxNXB|ODDhcoQhVkZvzsrCJJRwKGG3Z33lcpQhXE6IzsGtbY5lfWOnZDDu[YNzd3C2b4Ppd{BidmRiYYX0c5Bp[We7 NVfEepJWOjJyMkewPVc>
YD-8  M3fGb2Fxd3C2b4Ppd{BCe3OjeR?= MkPnNVAx|ryP MXGxbC=> NYXjZo0y[myxY3vzJJRp\SCJUz3IR4wucW6mdXPl[EBieG:ydH;zbZM> NV7aZXdXOjJyMkCwO|g>
HBx MXPBdI9xfG:|aYOgRZN{[Xl? MoPFNlXPxE1? MVK0PIg> NXPlRY94TE2VTx?= NGXYTWpz\WS3Y3XkJINmdGxiZHXheIghcW6mdXPl[EBjgSB|LV3B Mo\WNlIxOjByN{i=
U937  NF3rc|ZCeG:ydH;zbZMhSXO|YYm= MUm1NOKh|ryP NFTvT4MycA>? MlHCbY5pcWKrdIOgTGYucW6mdXPl[EBieG:ydH;zbZPDqA>? MUGyNVk6QDd|MR?=
HL60 MVvBdI9xfG:|aYOgRZN{[Xl? NYOwUVVrPDEQvF2= Ml32OFBucW5? NETpUldFVVOR Mmf0Zoxw[2u|IFLOSGMh[2:vcH;1coR{KGmwZIXj[UBmgHCxc4Xy[UBw\iCyaH;zdIhifGmmeXzz[ZJqdmViYX7kJGRPSSCocnHncYVvfGG2aX;u Mn;VNlE6QDN{OU[=
M-14 Ml7VRZBweHSxc3nzJGF{e2G7 NITj[pEzPc7:TR?= M4HCXlAvPWh? M4fUWeKhcW6qaXLpeJMh[m:2aDD0bIUh[3K3ZHWg[Zh1emGldD2gZY5lKGOxbYDveY5lNWmwZIXj[YQh[XCxcITvd4l{ NIr2NJMzOTl3NEm1PS=>
SK-BR-3 MX3BdI9xfG:|aYOgRZN{[Xl? NH\XV202OMLizszN M2i3VVJp MnX5Zoxw[2u|IHHwc5B1d3SrYzDEUmEh\nKjZ33lcpRifGmxbjDpcoR2[2WmIHL5JINwdWKrbnH0bY9vKG:oIGPNMVE3PCCjbnSgdoFlcWG2aX;u MmXoNlE6ODF|OE[=
MDA-MB-468 NWP4Nmc5SXCxcITvd4l{KEG|c3H5 MkHROVDDqM7:TR?= MUOybC=> NVvScmJC[myxY3vzJIFxd3C2b4TpZ{BFVkFiZoLh[41mdnSjdHnvckBqdmS3Y3XkJIJ6KGOxbXLpcoF1cW:wIH;mJHNONTF4NDDhcoQhemGmaXH0bY9v NUHtdHBmOjF7MEGzPFY>

... Click to View More Cell Line Experimental Data

In vivo In vivo Z-VAD-FMK administration has been shown previously to be nontoxic and to prevent apoptosis in animal models. Intraperitoneal HK-GBS injection leads to preterm delivery, and pretreatment with Z-VAD-FMK delays preterm delivery in mice. In OVA-sensitized mice,treatment of z-VAD-fmk inhibits allergen-induced leukocyte infiltration. Systemic injection of the pan-caspase inhibitor z-VAD-fmk immediately before OVA challenge reduced inflammatory cell accumulation, mucus hypersecretion, and Th2 cytokine release in OVA-sensitized/challenged mice. Treatment with z-VAD-fmk blocked terminal differentiation of lens epithelial cells and keratinocytes, the differentiation of monocytes into macrophages, and the differentiation of erythroid progenitors. z-VAD-fmk attenuated allergen-induced airway inflammation and hyperreactivity. Treatment with z-VAD-fmk in vivo also prevented subsequent T cell activation ex vivo[7].

Protocol

Cell Research:

[6]

+ Expand
  • Cell lines: human granulosa cell lines (GC1a, HGL5, COV434)
  • Concentrations: 50 μM
  • Incubation Time: 48 h
  • Method:

    To validate the efficacy of Z-VAD-FMK, three human granulosa cell lines (GC1a, HGL5, COV434) were treated for 48 h with etoposide (50 μg/ml) and/or Z-VAD-FMK (50 μM) under normoxic conditions. To mimic the ischemic phase that occurs after ovarian fragment transplantation, cells were cultured without serum under hypoxia (1 % O2) and treated with Z-VAD-FMK. The metabolic activity of the cells was evaluated by WST-1 assay. Cell viability was determined by FACS analyses. The expression of apoptosis-related molecules was assessed by RT-qPCR and Western blot analyses.


    (Only for Reference)
Animal Research:

[7]

+ Expand
  • Animal Models: CD1 mice
  • Formulation: dissolved in DMSO, diluted in PBS (final concentration of DMSO < 1%)
  • Dosages: 10 mg/kg
  • Administration: i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 93 mg/mL (198.93 mM)
Water Insoluble
Ethanol Insoluble warmed
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
2% DMSO+35 %PEG 300+2%Tween 80+ddH2O
For best results, use promptly after mixing.
6mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 467.49
Formula

C22H30FN3O7

CAS No. 187389-52-2
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Can you suggest an in vivo formulation of S7023 for animal studies?

  • Answer:

    For in vivo study of S7023, The IP formulation is 2% DMSO+35 % PEG 300+2% Tween 80+ddH2O up to 6 mg/ml. The gavage formula is 1%CMC-Na up to 30 mg/ml (suspensions).

  • Question 2:

    What is difference between S7023 & S8102?

  • Answer:

    Unlike S7023, S8102 does not require pretreatment with esterase for in vitro studies. This information was cited from the article: https://www.ncbi.nlm.nih.gov/pubmed/16973565.

Caspase Signaling Pathway Map

Related Caspase Products0

Tags: buy Z-VAD-FMK | Z-VAD-FMK supplier | purchase Z-VAD-FMK | Z-VAD-FMK cost | Z-VAD-FMK manufacturer | order Z-VAD-FMK | Z-VAD-FMK distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID